Overview Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Status: RECRUITING Trial end date: 2026-10-01 Target enrollment: Participant gender: Summary This is a Phase 3 trial of cadisegliatin as adjunctive therapy to insulin in participants with Type 1 Diabetes Mellitus.Phase: PHASE3 Details Lead Sponsor: vTv TherapeuticsTreatments: BID protein, humanTTP399